Jason Litten was named Chief Medical Officer of GENELUX Corp, effective January 2, 2026. As of November 15, 2026, GENELUX Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 2, 2026, naming 1 appointment (Form 8-K, January 2, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like GENELUX Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
GENELUX Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-02. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as GENELUX Corp files it.
Also on the record for GENELUX Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 4, 2026 | Stake report, Schedule 13G/A, by Aladar Szalay | 6.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Aladar Szalay | 8.2% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| July 25, 2025 | Stake report, Schedule 13G/A, by Aladar Szalay | 8.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs GENELUX Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on GENELUX Corp and the records around it.
GENELUX Corp elsewhere on the record
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch GENELUX Corp
Get an email when GENELUX Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on GENELUX Corp?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on GENELUX Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GENELUX Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-02 | In | Chief Medical Officer | 2026-01-02 | 8-K, 2026-01-02 |
Who leads GENELUX Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Jason Litten, appointed, effective 2026-01-02 (filed 2026-01-02).
New leaders reset buying decisions — get the Full Report on GENELUX Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at GENELUX Corp, with the record behind each one.
Find candidates like Chief Medical Officer at GENELUX CorpEvery change, in the filing's words
Appointed: Jason Litten, Chief Medical Officer, effective 2026-01-02
Appointment of Jason Litten, M.D. as Chief Medical Officer On January 2, 2026, the Company announced the appointment of Jason Litten, M.D. as the Company's Chief Medical Officer, effective as of January 2, 2026 (the " Effective Date ").
- Departure of Principal Officer or Named Executive Officer On December 30, 2025, Paul Scigalla, M.D. resigned as Chief Medical Officer of Genelux Corporation (the "Company"), effective immediately.
- Dr. Litten, 52, most recently served as the Chief Medical Officer of Chimeric Therapeutics, Ltd. since July 2022.
- Dr. Litten is an expert in clinical oncology with experience developing numerous therapeutics modalities.
- Dr. Litten notably developed some of the first CAR-T, TCR and NK cell clinical programs, as well as leading the clinical and preclinical development of numerous therapeutic monoclonal antibodies and orally available cancer medicines.
- From August 2019 to March 2022, Dr. Litten served as the Chief Medical Officer at Artiva Biotherapeutics, Inc. where he built and led Artiva's clinical and regulatory functions.
- During his time at Artiva, Dr. Litten contributed to launching two clinical NK cell therapy programs, raising over $200 million in private financing and establishing two foundational corporate partnerships.
Tools for this story
Each opens in a new tab, filled in for GENELUX Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
